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Summary  Glucantime  remains  the  ﬁrst-line  treatment  for  cutaneous  leishmania-
sis.  In  a  prospective  study,  we  evaluated  its  efﬁcacy  and  side  effects  in  patients
treated  in  Yazd  from  2010  to  2011.
Methods:  Patients  with  lesions  compatible  with  cutaneous  leishmaniasis  were  consid-
ered  eligible  for  inclusion  in  this  study  if  the  disease  was  conﬁrmed  parasitologically.
The  exclusion  criteria  were  as  follows:  the  patient  preferred  a  treatment  modal-
ity  other  than  Glucantime;  there  was  no  indication  for  treatment;  the  patient  had
underlying  kidney,  liver,  or  cardiac  disease;  or  was  pregnant  and  lactating.
Patients  with  ≤3  lesions  and/or  lesions  <3  cm  in  diameter  were  treated  with  Glu-
cantime  intralesionally  if  the  lesions  were  not  located  on  the  face,  neck  or  joints;
sporotrichoid;  or  superinfected  with  bacteria.  All  other  patients  were  prescribed
intramuscular  Glucantime  at  10—20  mg/kg/day  for  20  days.
Results:  The  failure  rate  for  patients  treated  with  one  course  of  Glucantime  was
22.6%  overall.  There  were  no  associations  between  age,  sex,  weight,  the  route  of
administration,  the  number  and  size  of  lesions,  the  adequacy  of  the  dose  of  the  drug
injected  intramuscularly,  the  number  of  intralesional  injections  (<6  or  ≥6)  and  the
duration  of  therapy.  The  only  factor  associated  with  failure  was  reported  previous
exposure  to  antimony  (p  value  0.047).  Adverse  effects  occurred  in  14.2%  of  patients
(22/155).
Conclusion:  Glucantime  is  an  effective  drug  for  the  treatment  of  cutaneous
leishmaniasis  in  central  Iran.  However,  because  cutaneous  leishmaniasis  heals  spon-
taneously  and  to  prevent  the  acquisition  of  resistance,  the  indications  for  treatment
in  each  region  should  be  deﬁned  carefully.
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utaneous  leishmaniasis  (CL)  occurs  in  two  forms
n Iran,  zoonotic  cutaneous  leishmaniasis  (ZCL)  and
nthroponotic  cutaneous  leishmaniasis  (ACL).  ZCL,
hich is  caused  by  Leishmania  major,  is  endemic  in
he northeastern,  southeastern  and  central  areas  of
ran [1].  ACL,  which  is  caused  by  Leishmania  trop-
ca, is  prevalent  in  large  and  medium-sized  cities  in
ran [2].
Pentavalent  antimony  is  the  ﬁrst  choice  for  the
reatment  of  cutaneous  leishmaniasis  of  both  the
ew World  and  Old  World  types,  including  the  type
f leishmaniasis  that  is  prevalent  in  Iran  [3—7].
owever,  concerns  about  the  resistance  of  parasites
o Glucantime  have  appeared  [8].  The  ﬁrst  report  of
he in  vitro  resistance  of  L.  tropica  to  Glucantime  in
ran was  published  in  2006  [9].  Previously  identiﬁed
isk factors  for  the  failure  of  treatment  with  Glu-
antime  are  body  weight  above  68  kg,  previous  anti-
eishmania  treatment,  having  ≥3  skin  lesions  and
ailure to  complete  the  treatment  schedule  [10].
A  prospective  study  was  designed  to  evaluate  the
ailure rate  and  identify  possible  factors  associated
ith failure  in  patients  treated  with  Glucantime  in
azd in  central  Iran  between  March  2010  and  March
011.
aterials and methods
atients
ll  patients  with  skin  lesions  compatible  with  CL
nd parasitologically  conﬁrmed  disease  who  were
eferred  to  the  Yazd  Health  Center  from  March  2010
o March  2011  were  considered  eligible  for  inclusion
n this  study.
Patients  from  known  foci  of  either  zoonotic
utaneous  leishmaniasis  or  anthroponotic  were
ncluded.  The  following  patients  were  excluded:
atients who  preferred  a  treatment  modality  other
han Glucantime  (meglumine  antimonite);  those
ho had  no  indication  for  therapy;  patients  with
nderlying  conditions,  such  as  diabetes,  liver  dis-
ase, cardiac  disease,  and  renal  disease;  and
regnant  and  lactating  women.
Parasitological  conﬁrmation  was  performed  by
iemsa staining  (direct  smear).  The  size  of  the
esion was  deﬁned  as  the  diameter  of  the  largest
esion measured  in  millimeters.esign
atients  enrolled  in  the  study  completed  a ques-
ionnaire  covering  age,  sex,  weight,  number  of
A
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esions,  size  of  the  largest  lesion,  route  of  drug
dministration  (intramuscular  or  intralesional),
ose of  Glucantime,  duration  of  therapy,  outcome
failure or  cure)  and  adverse  events.
Most  patients  were  treated  within  2—3  months
fter the  appearance  of  lesions.
Patients with  ≤3  lesions  and  patients  who  had
esions  <3  cm  in  diameter  were  treated  intralesion-
lly if  the  lesions  were  not  located  on  the  face  or
eck or  over  the  joints;  sporotrichoid;  or  superin-
ected with  bacteria.  Glucantime  (Aventis,  Paris,
rance; supplied  in  5  ml  ampules  containing  81  mg
ntimony/ml)  was  injected  2  times  per  week  for
 total  number  of  injections  from  6  to  15  [11].
ntradermal  injections  of  0.3—1.5  ml  of  drug  were
dministered  until  the  lesion  faded.
All  other  patients  were  prescribed  intramuscular
njections of  Glucantime  at  20  mg/kg/day  (maxi-
um 3  ampules/day)  that  were  administered  in  2—3
ivided doses  for  two  weeks  for  ZCL  and  20  days
or ACL  according  to  the  national  guidelines  dis-
ributed  by  the  Iranian  Center  for  Disease  Control.
atients  who  required  more  than  2  ampules  based
n their  weight  received  less  than  20  mg/kg/day.
ure was  conﬁrmed  by  a  negative  direct  smear,
nd failure  was  deﬁned  as  the  persistence  of an
ctive lesion,  the  appearance  of  new  lesions  in  the
eriphery of  the  primary  lesion,  the  persistence  of
nduration and  lymphadenopathy,  or positive  direct
mears 2—4  weeks  after  the  completion  of  one
ourse of  treatment  with  Glucantime.  The  intrale-
ional injections  and  the  evaluation  of  patients
ere performed  by  four  infectious  disease  special-
sts coordinated  by  the  ﬁrst  author.  Follow-up  visits
o assess  patients  for  failure  were  arranged  2—4
eeks after  the  completion  of  therapy.  In  the  case
f relapse  or  a failure  to  respond  to  the  ﬁrst  course
f therapy,  the  patients  were  retreated  as  decided
y the  clinician.
The patients  were  divided  into  3  treatment
roups: intralesional,  intramuscular,  and  intrale-
ional plus  intramuscular  for  patients  who  did  not
olerate the  IM  injections  because  of  pain  or  the
ntralesional  injection  because  of  severe  inﬂamma-
ion and  irritation.
The potential  risk  factors  associated  with  a fail-
re to  respond  to  Glucantime  were  also  studied.
atients were  also  assessed  for  adverse  side  effects
f Glucantime  treatment  at  each  visit.  Blood  labo-
atory tests  were  not  consistently  requested  for  all
atients.nalysis
he  data  were  analyzed  with  SPSS  (18).  Chi-square,
isher’s exact  and  T  tests  were  used.  p  values  less
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than  0.05  were  considered  signiﬁcant  for  differ-
ences  between  groups.
This  study  was  performed  as  a  thesis  and
approved by  the  ethical  board  of  research  deputy
of our  medical  faculty.
3-Hypothesis
Glucantime  (SbV)  is  the  ﬁrst-line  treatment  for
cutaneous  leishmaniasis  in  Iran.  However,  because
resistance  to  this  drug  has  been  reported,  its  efﬁ-
cacy and  adverse  side  effects  should  be  regularly
monitored.
Results
Among  the  164  patients  who  were  enrolled  into
the study,  9  were  excluded  because  they  refused
injections with  Glucantime,  preferring  cryother-
apy (4  patients)  or  treatment  with  oral  agents  (5
patients).  The  majority  of  patients  were  referred
during  the  autumn  and  winter.  One  hundred  and
ﬁfty-ﬁve  patients  were  treated  with  Glucantime,
but the  outcome  was  evaluable  for  only  137  patients
(88.5%),  who  were  analyzed.  Seventy-six  patients
were male  (55.5%),  and  the  mean  age  of  the
patients was  30.8  ±  20.1  years  (8  months  to  84
years).  The  mean  number  of  lesions  was  2.2  ±  2.06
(1—15), and  the  mean  size  of  the  largest  lesion
was 29.6  ±  23.4  mm  (3—120).  Thirty-eight  patients
were  treated  intralesionally,  and  95  patients  were
treated intramuscularly.  Four  patients  were  treated
both intralesionally  and  intramuscularly  and  omit-
ted from  the  analysis.
The  overall  failure  rate  for  patients  treated
with one  course  of  Glucantime  was  22.6%  (31/137)
(Table 1).  As  shown  in  Table  1,  there  were  no  asso-
ciations  between  age,  sex,  weight,  the  route  of
administration  (intramuscular  or  intralesional),  the
number and  size  of  lesions,  the  dose  (≥10  mg/kg
or <10  mg/kg)  of  intramuscularly  injected  drug,
an adequate  number  (6—15)  of  intralesional  injec-
tions, the  amount  of  Glucantime  administered  or
the duration  of  therapy  in  the  present  study.  Only  1
patient was  compliant  with  injecting  three  ampules
of Glucantime  per  day  intramuscularly.  The  only
factor associated  with  failure  was  reported  previ-
ous exposure  to  Glucantime  (p  value  0.047).
Nine patients  were  excluded  from  the  analysis.
The lesions  of  6  patients  (66.6%)  healed:  the  lesions
of two  pregnant  women  (one  spontaneously  and  one
after the  use  of  herbal  medicine  and  paromomycin
ointment), two  30  mm  lesions  in  1  patient  (spon-
taneously),  one  lesion  after  a  single  cryotherapy
t
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reatment  session,  one  lesion  measuring  50  mm
fter treatment  with  azithromycin  (250  mg  bid  for
 days),  and  one  lesion  after  treatment  with  keto-
onazole  (2  tablets  per  day  for  20  days).
Clinically  observed  adverse  side  effects  of  Glu-
antime  occurred  in  22/155  patients  (14.2%)  in  the
resent study.  These  side  effects  included  a hyper-
ensitivity  reaction  in  9  patients  (5.8%);  cellulitis  at
he site  of  the  intralesional  injection  in  3  patients
1.9%);  syncope  after  injection  in  2  patients  (1.3%),
ne instance  of  which  was  associated  with  hypoten-
ion and  required  the  administration  of  vasotonic
gents; severe  myalgia  in  2  patients  (1.3%);  and
izziness,  hypoglycemia,  urinary  retention,  deep
bscess formation  after  local  injection,  bullous
ormation following  cryotherapy,  severe  headache
fter  local  injection  and  a severe  generalized
czematous  reaction  each  in  1  patient  (3.9%).  Shin-
les was  observed  concomitantly  in  three  patients.
iscussion
he  failure  rate  after  one  course  of  therapy  with
lucantime  administered  either  intramuscularly  or
ntralesionally  in  central  Iran  in  the  present  study
as 22.6%  (31/137).  The  failure  rate  evaluated
—4 weeks  after  the  completion  of  one  course
f treatment  with  intramuscular  Glucantime  was
4.2% (23/95).  The  present  study  included  both
CL and  ZCL.  The  reported  failure  rates  for  one
ourse of  standard  intramuscular  Glucantime  for
4 days  in  Iran  are  7%  in  the  eastern  region;  16%,
4.9%,  and  59%  in  the  southern  region;  and  16.7%
n the  northern  region  among  patients  treated
ith 20  mg/kg/day  [12].  In  another  study  in  Iran,
n vitro  and  in  vivo  resistance  was  observed  in  11%
f isolated  L.  tropica  strains  [9].  The  cure  rate
n the  present  study  was  slightly  lower  than  the
ates reported  from  two  clinical  trials  in  Bolivia
nd Colombia  (83%)  [3].  Two  studies  from  Pakistan
evealed  failure  rates  of  19%  and  45%  [8,13].  Two
tudies from  South  America  revealed  47%  and  57.9%
ailure rates  in  patients  treated  with  20  mg/kg/day
or 20  days  [10,14].  The  wide  range  of  failure  rates
n different  studies  is  due  to  the  different  par-
site species,  different  treatment  schedules,  and
ifferent intervals  between  the  evaluation  of  the
esponse  and  the  termination  of  therapy  because
f the  possibility  of  spontaneous  resolution  in  those
valuated  later  [12].  We  evaluated  our  patients  4
eeks after  the  completion  of  therapy  to  avoid
he inclusion  of  patients  who  may  have  recovered
pontaneously.  A  history  of  previous  treatment  with
lucantime  was  the  only  factor  associated  with
ailure in  this  study.  This  ﬁnding,  which  could  be
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Table  1  Demographic  and  clinical  characteristics  of  patients  with  cutaneous  leishmaniasis  and  their  responses  to
Glucantime.
Variable  Cure  N  (%)  Failure  N  (%)  p  value  Test  applied
Age  group  (years)
<18  26  (24.5)  9  (29.1)  0.261  Chi-square
18—59  72  (67.9)  17  (54.8)
>60  8  (7.5)  5  (16.1)
Sex
Male 59 (77.6)  17 (22.4)  0.935  Chi-square
Female 47 (77)  14 (23)
Type  of  injection
Intramuscular  (IM)  72  (75.8)  23  (24.2)  0.470  Chi-square
Intralesional  (IL)  31  (81.6)  7  (18.4)
Previous  treatment  with  Glucantime
Yes  5  (50)  5  (50)  0.047  Fisher’s  exact
No  101  (79.5)  26  (20.5)
Number  of  lesions
≤3  94  (79.7)  24  (20.3)  0.139  Chi-square
>3  12  (63.1)  7  (36.9)
Lesion  size  (mm)
≤30  76  (76.8)  23  (25.2)  0.785  Chi-square
>30  30  (78.9)  8  (21.1)
Weight  of  patient  (kg)
≤40  18  (69.2)  8  (30.8)  0.270  Chi-square
>40 88  (79.3)  23  (20.7)
Dose  of  Glucantime  (IM)
≥10  mg/kg/day 61 (78.2)  17 (21.8)  0.551  Fisher’s  exact
<10  mg/kg/day 13 (72.2)  5  (17.8)
Number  of  IL  injections
6—15  20 (66.6)  5  (35.4)  1.000  Fisher’s  exact
<6 10 (76.9)  3 (23.1)
Amount  of  Glucantime/kg/day  (mg) 12.9  ±  3.97  12.37  ±  3.48  0.601  T-test
Duration  of  therapy  in  intramuscularly  treated  patients  (days)
<10 12 (80)  3 (20)  0.910  Chi-square
10—14  31 (75.6)  10 (24.4)
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d≥15 29 (74.3)  
ue  to  acquired  resistance,  has  been  observed  in
wo other  studies  [3,10].  Practices  that  expose  the
arasites  to  drug  pressure  lead  to  the  selection
f species  of  the  parasite  that  are  resistant  to
bV [15].  Resistance  to  Glucantime  is  an  important
ssue  because  there  are  few  other  drugs  available
or the  treatment  of  cutaneous  leishmaniasis  [16].
ross-resistance  has  been  observed  between  Pen-
ostam (SSG)  and  Glucantime,  which  further  limits
he treatment  options  available  in  Iran  [9].
Regarding  the  clinical  adverse  side  effects
bserved in  the  present  study,  hypersensitivity  was
he most  frequent  and  was  primarily  observed  fol-
owing local  injection.  In  another  study  in  Iran
omparing  the  intralesional  injection  of  Glucan-
ime  with  zinc  sulfate,  8.52%  of  patients  treated
ith  Glucantime  developed  pruritus,  erythema
nd peripheral  scaling  [17].  Severe  pain  associ-
ted with  local  injection  and  resulting  in  syncope
f
s
r10 (25.7)
nd hypotension,  which  was  observed  in  one  of
ur patients,  was  a potentially  serious  adverse
ffect. For  this  subgroup  of  patients,  other  treat-
ent modalities,  such  as  an  alternative  antimony
chedule,  can  be  used  [18].  Myalgia,  which  was
eported  by  2  patients  in  the  present  study,  was
eported  in  up  to  68%  of  patients  in  a trial  in
hich patients  were  treated  with  20  mg/kg/day
lucantime intravenously  for  20  days  [19].  In  a
etrospective  study  performed  in  Tunisia,  myalgia
as the  third  most  frequent  side  effect  of  Glu-
antime [20].  Although  pentavalent  antimonials,
uch as  Glucantime,  have  been  used  since  1911
21], some  of  the  adverse  side  effects  observed
n the  present  study,  including  hypoglycemia  in  a
iabetic patient,  urinary  retention,  deep  abscess
ormation,  severe  headache,  and  concomitant
hingles, have  not  been  mentioned  in  previous
eports [8,12,17,19]. Therefore,  the  side  effects
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of  Glucantime  should  be  monitored  repeatedly,
and because  of  the  self-limiting  nature  of  cutaneous
leishmaniasis  in  the  majority  of  cases  and  to  pre-
vent the  development  of  resistance  to  Glucantime,
this drug  should  be  reserved  for  the  treatment  of
severe, progressive  or  disﬁguring  disease.
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